The European Medicines Agency (EMA) has recommended the approval of Emblaveo, a new antibiotic for the treatment of certain bacterial infections. Emblaveo combines aztreonam and avibactam, and is recommended for treating complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia, and infections caused by specific types of bacteria.
The EMA's endorsement is based on safety and efficacy data for the active components of Emblaveo, as well as findings from two phase 3 randomized trials
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: